Want to see CMPX full AI Analyst Report?
Top Page
Compass Therapeutics
(NASDAQ:CMPX)
Select Model
Select Model
Rating:42Neutral
Price Target:
$0.80
▼(-67.00% Downside)
Action:Reiterated
Date:10/06/26
CMPX scores low primarily due to weak financial performance (large losses and heavy cash burn) and bearish technicals (price well below major moving averages with negative MACD). Valuation signals are limited by negative earnings and no dividend support, and a recent FDA pushback adds meaningful regulatory and timeline risk.
Positive Factors
Low leverage and substantial assets
Low leverage gives Compass greater financial flexibility while it advances its clinical pipeline. The modest debt burden reduces fixed financial obligations and leaves more room to direct capital toward research, trials, and regulatory work, although continued losses can still erode this cushion.
Negative Factors
Heavy and persistent cash burn
Sustained negative operating and free cash flow shows that Compass is consuming capital rather than funding operations internally. Continued burn increases dependence on external financing, can constrain development choices, and may pressure the balance sheet if clinical and regulatory expenses remain elevated.
Read all positive and negative factors
Positive Factors
Negative Factors
Low leverage and substantial assets
Low leverage gives Compass greater financial flexibility while it advances its clinical pipeline. The modest debt burden reduces fixed financial obligations and leaves more room to direct capital toward research, trials, and regulatory work, although continued losses can still erode this cushion.
Read all positive factors
Compass Therapeutics (CMPX) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$150.37M
Dividend YieldN/A
Average Volume (3M)5.83M
Price to Earnings (P/E)―
Beta (1Y)2.21
Revenue GrowthN/A
EPS Growth10.44%
CountryUS
Employees39
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.41
Shares Outstanding180,087,920
10 Day Avg. Volume5,519,184
30 Day Avg. Volume5,829,869
Financial Highlights & Ratios
PEG Ratio-0.77
Price to Book (P/B)4.30
Price to Sales (P/S)0.00
P/FCF Ratio-17.22
Enterprise Value/Market Cap1.59
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-323.63
Enterprise Value/Ebitda-3.32
Forecast
1Y Price Target
$6.13Price Target Upside152.06% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering11
EPS Forecast (FY)-0.5
Revenue Forecast (FY)N/A
Compass Therapeutics Business Overview & Revenue Model
Company Description
Compass Therapeutics, Inc. is a biopharmaceutical firm focused on developing cancer treatments, with several therapeutic candidates currently in clinical trials. The company's work involves creating antibody-based medicines designed to address a v...
How the Company Makes Money
As a clinical-stage biopharmaceutical company, Compass Therapeutics does not primarily generate revenue from product sales because it does not have widely disclosed marketed/approved products. Its earnings, when present, are typically driven by no...
Compass Therapeutics Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
63
Positive
Cash Flow
24
Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0.00 | 0.00 | 850.00K | 0.00 | 0.00 | 0.00 |
| Gross Profit | -738.00K | -1.47M | 850.00K | 0.00 | 0.00 | 0.00 |
| EBITDA | -71.96M | -65.02M | -47.62M | -40.60M | -34.96M | -80.19M |
| Net Income | -73.45M | -66.49M | -49.38M | -42.49M | -39.23M | -82.18M |
Balance Sheet | ||||||
| Total Assets | 190.17M | 219.59M | 140.40M | 156.88M | 199.65M | 153.76M |
| Cash, Cash Equivalents and Short-Term Investments | 179.88M | 208.91M | 126.72M | 152.46M | 186.61M | 144.51M |
| Total Debt | 9.63M | 9.83M | 6.63M | 1.73M | 2.94M | 4.04M |
| Total Liabilities | 24.12M | 22.80M | 15.17M | 8.34M | 18.01M | 13.68M |
| Stockholders Equity | 166.05M | 196.79M | 125.23M | 148.54M | 181.64M | 140.08M |
Cash Flow | ||||||
| Free Cash Flow | -55.05M | -49.17M | -44.90M | -40.65M | -34.34M | -21.23M |
| Operating Cash Flow | -54.79M | -49.14M | -44.85M | -40.62M | -34.13M | -19.67M |
| Investing Cash Flow | -65.08M | -93.31M | 46.77M | 26.96M | -151.20M | -1.77M |
| Financing Cash Flow | 129.94M | 129.61M | 17.34M | 2.94M | 75.76M | 118.61M |
Compass Therapeutics Technical Analysis
Negative
2.43
Price Trends
1.71
Negative
1.90
Negative
3.37
Negative
Market Momentum
-0.24
Negative
23.81
Positive
9.57
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CMPX, the sentiment is Negative. The current price of 2.43 is above the 20-day moving average (MA) of 0.98, above the 50-day MA of 1.71, and below the 200-day MA of 3.37, indicating a bearish trend. The MACD of -0.24 indicates Negative momentum. The RSI at 23.81 is Positive, neither overbought nor oversold. The STOCH value of 9.57 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for CMPX.
Compass Therapeutics Risk Analysis
Compass Therapeutics disclosed 77 risk factors in its most recent earnings report. Compass Therapeutics reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Compass Therapeutics Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
47 Neutral | $246.79M | -1.32 | -33.22% | ― | 215.59% | 22.48% | |
47 Neutral | $479.72M | -31.72 | -13.08% | ― | ― | 29.73% | |
44 Neutral | $509.88M | -5.58 | -38.46% | ― | -87.03% | -179.91% | |
43 Neutral | $51.51M | -0.21 | 108.75% | ― | 32.43% | 7.41% | |
42 Neutral | $150.37M | -2.01 | -38.71% | ― | ― | 10.44% |
* Healthcare Sector Average
CMPX
Compass Therapeutics
0.83
-3.27
-79.68%
CTMX
CytomX Therapeutics
2.51
-1.11
-30.57%
GOSS
Gossamer Bio
9.58
-164.82
-94.51%
BCYC
Bicycle Therapeutics
3.60
-4.69
-56.57%
MNPR
Monopar Therapeutics Inc
74.23
-3.42
-4.40%
Compass Therapeutics Corporate Events
Business Operations and StrategyProduct-Related AnnouncementsRegulatory Filings and Compliance
Compass Therapeutics Faces FDA Pushback on Tovecimig Trial
Negative
Sep 22, 2026
On Sept. 22, 2026, Compass Therapeutics reported that the U.S. Food and Drug Administration recommended a new trial demonstrating an overall survival benefit before the company submits a Biologics License Application for its investigational antibo...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.